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Abstract
We report the emergence in Kenya during 1997-1999 of typhoid fever due to Salmonella enterica
serovar Typhi resistant to ampicillin, tetracycline, chloramphenicol, streptomycin, and cotrimoxazole.
Genotyping by pulsed-field gel electrophoresis of XbaI-digested chromosomal DNA yielded a single
cluster. The multidrug-resistant S. Typhi were related to earlier drug-susceptible isolates but were
unrelated to multidrug-resistant isolates from Asia.
Salmonella enterica serovar Typhi causes approximately 10 million cases of typhoid that result in 600,000
deaths each year, mostly in developing countries (1). The antibiotics that form the mainstay of therapy in
developing countries are chloramphenicol, ampicillin, and cotrimoxazole. Multidrug-resistant (MDR) strains
of S. Typhi (resistant to all the above antimicrobial drugs) have caused outbreaks in the Indian subcontinent,
Southeast Asia, and the Middle East since 1987 (2). Genetic studies have shown that resistance is encoded
on an HI1 incompatibility plasmid and is transferable (3). MDR S. Typhi has not caused problems in Africa,
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Figure 1. Dendogram showing genetic relatedness of Salmonella Typhi from Kenya and Asia. H1 and
H2: MDR S. Typhi from Hong Kong; K: MDR S. Typhi from Kuwait; B: MDR S. Typhi from...
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except in South Africa (4), nor in South and Central America (5), and most isolates have remained fully
susceptible. During 1997-1999, a number of isolates of MDR S. Typhi were identified from patients with
typhoid in Nairobi, Kenya. We have examined their genotypic relationship to each other, to sensitive strains
from Nairobi, and to MDR S. Typhi from Southeast Asia.
The Study
We analyzed isolates of S. Typhi obtained in the Kenyatta National Hospital from blood cultures of 16 adults
with typhoid from 1988 to 1993; from 22 cultures of 19 adults and 3 children from 1997 to 1999; and from
17 representative MDR S. Typhi strains collected from 1990 to 1995 (6) from Pakistan (7), Hong Kong (4),
Bangladesh (3), Kuwait (1), and India (1). We did not have access to isolates from 1994 to 1996, when no
active surveillance was conducted. MICs of ampicillin, coamoxyclav, cefuroxime, cotrimoxazole,
chloramphenicol, gentamicin, streptomycin, tetracycline, nalidixic acid, and ciprofloxacin were determined
by the E-test method (AB Biodisk, Solna, Sweden).
Macrorestricted (using XbaI) chromosomal DNA from the S. Typhi isolates was separated by pulsed-field gel
electrophoresis (PFGE) with a CHEF DRII system (Bio-Rad Labs, Richmond, VA). The gels were stained with
ethidium bromide and photographed on an ultraviolet transilluminator. Banding patterns were compared
(8), and dendrograms of relatedness were constructed by data clustering using the unweighted pair
grouping arithmetic averaging method (Molecular Fingerprinting Program version 1.4.1, BioRad).
Conjugation experiments, plasmid extraction and electrophoresis, and incompatibility grouping were
performed as described (7).
All 16 S. Typhi isolates from 1988-1993 were fully sensitive to all the drugs tested (MIC 0.012-0.016 mg/L
for ciprofloxacin to 1-3 mg/L for chloramphenicol). In contrast, 18 (82%) of the 22 S. Typhi from 1997-1999
were resistant to ampicillin, tetracycline, and chloramphenicol (MICs all > 32 mg/L), as were the 17 isolates
from Asia. The first two MDR S. Typhi from Kenya were detected from blood cultures from two adults in
March 1997. Active surveillance is ongoing, and multidrug resistance is detected in approximately 65% of
all S. Typhi isolates to date. As we did not have access to isolates from 1994-1996, we cannot be certain that
MDR S. Typhi did not emerge earlier than 1997.
All the Kenyan MDR S. Typhi isolates came from indigenous patients with no known history of recent travel
outside the country. The Kenyan MDR isolates remained sensitive to co-amoxyclav, cefuroxime, gentamicin,
nalidixic acid, and ciprofloxacin. The Kenyan MDR S. Typhi all transferred their full resistance phenotype to
Escherichia coli K12 on 98-100 MDa plasmids of inc HI1 (or inc HI1 cross-reacting with inc FIIA).
Figure 2. XbaI restriction endonuclease fragment patterns of representative Salmonella Typhi isolates
from various countries. Lanes 1 and 19, molecular size standard; Lane 2, B1 from Bangladesh; Lane 3,
I1 from India; Lanes...
All 22 MDR and 16 sensitive S. Typhi were analyzed by PFGE. As all 22 MDR isolates were similar by PFGE,
only two representative strains were selected for further analysis. In addition, 5 representative sensitive S.
Typhi and 11 representative MDR strains from Asia were analyzed for similarity by using dendograms. The
sensitive S. Typhi (1987-1992) had a number of different genotypes. The MDR S. Typhi were identical, but
differed from the sensitive isolates by more than seven bands, indicating they were different strains.
However, on the dendogram comparing MDR S. Typhi from Asia and the S. Typhi from Kenya (both MDR
and sensitive), the Kenyan isolates formed one cluster, with the nearest (but genotypically quite distinct)
other cluster being the Pakistani MDR S. Typhi (Figure 1 and Figure 2).
Conclusions
The emergence of an MDR S. Typhi strain in Kenya is of concern because resistance to first-line antibiotics
that are also commonly used for treatment of other bacterial infections in hospitals may pose a major
challenge to health care. Although these newly emerged MDR S. Typhi are sensitive to nalidixic acid and
ciprofloxacin, their MICs are five and ten times higher, respectively, than those of the sensitive S. Typhi from
1988-1993. Although fluoroquinolones are not widely available in Kenya, they may be needed to treat MDR
S. Typhi, and resistance will lead to problems with treatment, as in Asia (9). Multidrug-resistant S. Typhi
isolates from Kenya produced an indistinguishable PFGE pattern that was related to those of sensitive
strains but unrelated to those of MDR S. Typhi from Asia. This finding implies that the Kenyan MDR S. Typhi
are most likely to have arisen from sensitive isolates by acquisition of resistance plasmids from antibiotic-
resistant enteric bacteria. Plasmids of incompatibility group HI1 are those most frequently found in S. Typhi,
but we did not detect them in any of our nontyphoidal salmonellae with the same plasmid-encoded
resistance (7).
We observed the emergence of S. Typhi resistant to all first-line drugs used for treatment of typhoid in
Kenya and in many other African countries. Laboratories in Kenya should perform surveillance by routinely
testing S. Typhi for susceptibility to first-line treatment drugs and to nalidixic acid to detect quinolone
resistance. Effective surveillance for this newly emerged MDR S. Typhi in Africa and other developing
regions of the world where MDR S. Typhi has not yet emerged would ensure prompt diagnosis,
susceptibility testing, and appropriate antimicrobial chemotherapy.
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